News – Page 17 – Alligator Bioscience

2021-12-16

Alligator Bioscience Announces Trial Update and Early Readout for ATOR-1017 Confirming Biomarker, Safety & Tolerability Data

Lund, Sweden, December 16, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced an update on the on-going clinical Phase I ...

2021-12-15

Lund, Sweden and Seattle Washington, December 15, 2021 – Alligator Bioscience AB (“Alligator”) and Aptevo Therapeutics (“Aptevo”) (NASDAQ: A ...

2021-12-02

Alligator Bioscience AB (publ) ("Alligator" or the "Company") has completed the rights issue of ordinary shares (the "Ri ...

2021-12-01

Alligator Bioscience AB (publ) ("Alligator" or the "Company") announces that the Company’s rights issue of shares (the “Righ ...

2021-11-29

Regulatory

rights issue of shares (the “Rights Issue”) ended on 26 November 2021. The preliminary outcome shows that the Rights Issue has been oversubs ...

2021-11-12

Poster presentation to highlight the ability of ATOR-1017 to activate and rescue tumor infiltrating exhausted T cells in synergy with PD-1 L ...

2021-11-12

Poster Presentation to highlight our Neo-X-Prime™ platform that aims to enable antigen presenting cells to efficiently enhance priming of tu ...

2021-11-12

Poster presentation to highlight the design of Optimize-1, evaluating mitazalimab in combination with chemotherapy in patients with metastat ...

2021-11-12

Data support Advancement into the Clinic Lund, Sweden, and Seattle Washington, November 12, 2021 – Alligator Bioscience AB (“Alligator”) and ...